Anupam Rasayan India: The Exchange has received revised Disclosure
Anupam Rasayan India (ANURAS) filed a disclosure titled "The Exchange has received revised Disclosure". The company is valued at about ₹13,479 crore.
What happened
Anupam Rasayan India (ANURAS) filed a disclosure with the exchanges on 9 November 2026 at 10:52 AM titled "The Exchange has received revised Disclosure".
Company snapshot
Anupam Rasayan India is a small-cap company in the Chemicals sector, with a market value of about ₹13,479 crore.
The stock last traded at ₹1,183.9, against a 52-week range of ₹1,059.1–₹1,415 (16.3% below the high).
Before this filing the shares had moved +0.0% over the month and −4.2% over three months. Average daily turnover over the last 20 sessions was about ₹44.32 crore.
Promoters held 59.07% at the end of Q2 FY27; 32.85% of promoter shares were pledged. Foreign institutions owned 8.66% and domestic institutions 2.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 731 | 44.4 | 3.93 |
| Q3 FY26 | 512 | 49 | 4.31 |
| Q4 FY26 | 636 | 42.7 | 3.75 |
| Q1 FY27 | 655 | 38.6 | 3.39 |
| Q2 FY27 | 806 | 50 | 4.39 |
What history shows
This is not the company's first pledge disclosure: BCEIE has 6 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.2% on average the next trading day and was down 0.5% on average after five days (6 filings with price data).
Across 18 similar disclosures by other Chemicals companies, shares moved +0.8% on average the next day and +1.6% over five days; 50% of them rose the next day.
Market-wide, 590 pledge filings with an impact score of 50 or more saw an average next-day move of +0.7%, with 52% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 6 Oct 2026 | The Exchange has received the Disclosures of reasons for encumbrance… | +0.1% | +0.1% |
| 6 Oct 2026 | The Exchange has received Disclosure under Regulation 31(1) and… | +0.1% | +0.1% |
| 5 Oct 2026 | The Exchange has received Disclosure under Regulation 31(1) and… | +0.6% | −1.0% |
| 5 Oct 2026 | The Exchange has received Disclosure under Regulation 31(1) and… | +0.6% | −1.0% |
| 17 Aug 2026 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations,… | +0.1% | +3.8% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers
- Anupam Rasayan India Q2 2027 Earnings Call Is Live
- Anupam Rasayan posts record quarterly revenue of Rs. 821 crore in Q2 FY27
- Anupam Rasayan Reports 21% Revenue Growth in H1 FY27 at ₹1,489 Crore
- Anupam Rasayan Builds Fluorine-to-Formulations Platform
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.